| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2a updated data readout example | TN-201 (Adeno-Associated Virus Serotype 9 Gene Replacement Therapy) MYBPC3-associated Hypertrophic Cardiomyopathy (HCM) — adult patients (monotherapy) | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Cardiovascular System | |
Phase 1b/2a updated data readout example | TN-201 (Adeno-Associated Virus Serotype 9 Gene Replacement Therapy) MYBPC3-associated Hypertrophic Cardiomyopathy (HCM) — adult patients (monotherapy) | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Cardiovascular System | |
Phase 1b/2a updated data readout example | TN-201 (Adeno-Associated Virus Serotype 9 Gene Replacement Therapy) MYBPC3-associated Hypertrophic Cardiomyopathy (HCM) — adult patients (monotherapy) | Phase 1b/2a | — | Subscribe to access the data. | Gene Therapies | Cardiovascular System |
Recent Updates
Recently added Catalysts
Tenaya Therapeutics, Inc.$0.87
+0.01 (+1%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
167.63 M
EPS
-0.47
P/E Ratio
-
Value Trade
4.31 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
225.00 K
R&D Expenses
14.84 M
Operating CF
-19.23 M
Total Assets
135.07 M
Total Liabilities
28.88 M
Equity
106.19 M
D/E Ratio
12,345
-14.17 %
Week
9.5 %
1 Month
24.6 %
3 Month
-33.97 %
6 Month
-96.04 %
5 Year
-96.04 %
All Time
Cash Data
Cash Position
80.89 M
Monthly Burn
6.41 M
Runway
10.7 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
3.85 M
52 Week Range
0.43 - 2.35
% held by Insiders
2.66 %
% held by Institutions
23.08 %
Enterprise Value
96.86 M
Total Shares
217.08 M
Short %
15.73 %
Float Shares
166.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tenaya Therapeutics, Inc.
290Total events
4Upcoming
33Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 4
Event history 286
Q3 2026
◆Additional DataTN-201Clinical Data
Additional long-term follow-up data for both dose levels expected in second half of 2026
MYBPC3-associated hypertrophic cardiomyopathysource ↗
Jun 4, 2026
◆Oral PresentationPresentation
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026
Jun 3, 2026
●Oral PresentationTN-201Presentation
Management webcast conference call to review MyPEAK-1 interim data
MYBPC3-associated hypertrophic cardiomyopathysource ↗
Jun 3, 2026
▲Topline ReadoutTN-201Clinical Data
Interim data from MyPEAK-1 showing improvements in cardiac remodeling and symptoms
MYBPC3-associated hypertrophic cardiomyopathysource ↗
Jun 3, 2026
▲EMA PrimeTN-201Ex-US Regulatory
TN-201 granted PRIME designation by EMA
MYBPC3-associated hypertrophic cardiomyopathysource ↗
Jun 3, 2026
▲FDA Feedback ReceivedTN-201FDA Meeting
TN-201 pediatric indication accepted into FDA's Rare Disease Evidence Principles process
MYBPC3-associated hypertrophic cardiomyopathy (pediatric biallelic)source ↗
Jun 3, 2026
◆Enrollment UpdateTN-201Trial
Continuing to enroll adults at 6E13 vg/kg dose in expansion cohort
MYBPC3-associated hypertrophic cardiomyopathysource ↗
May 15, 2026
◆Late-BreakerTN-401Presentation
Late-breaking oral presentation of new clinical data from RIDGE-1 trial of TN-401 at ASGCT 2026
PKP2-associated ARVCsource ↗
May 15, 2026
◆Oral PresentationTN-401Presentation
Oral presentation of interim data from RIDGE-1 trial at ASGCT 2026
PKP2-associated ARVCsource ↗
May 15, 2026
◆Timing GuidanceTN-401Presentation
Webcast conference call to discuss TN-401 data at ASGCT 2026
PKP2-associated ARVCsource ↗
May 15, 2026
Drug Pipeline Intelligence
D31
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 575 of 911)
Percentile RankTenaya Therapeutics, Inc. faces pipeline headwinds (31/100), with $38M risk-adjusted pipeline value, led by TN-201 in Hypertrophic Cardiomyopathy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TN-201 Gene therapy | Hypertrophic Cardiomyopathy | Phase 1 | NCT05836259 | 24% | $28M | RECRUITING | 30 | STALLED | D (38) | Aug 1, 2032 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TN-201 Fast TrackOrphanRare Pediatric | MYBPC3-associated hypertrophic cardiomyopathy (HCM) | Phase 1b/2 | 2026-06-03 | All evaluable patients experienced enhancements in clinical measures; Cohort 1 patients sustained benefits as far out as two years; Cohort 2 patients showed greater symptom relief and improved cardiac function at earlier timepoint; Improvements in multiple clinical parameters of disease including echocardiographic measures of hypertrophy; Three patients had improvements in exercise capacity by at least one measure; Cardiac troponin improved or remained stable in five of six patients; NT-pro BNP improved in three patients; All six evaluable patients achieved reductions in left ventricular mass index (LVMI); Five of six demonstrated reductions in one or more measures of wall thickness Read More | Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Read More | |
TN-201 Fast TrackOrphanRare Pediatric | MYBPC3-associated hypertrophic cardiomyopathy (HCM) | Phase 1b/2 | 2026-06-03 | All evaluable patients experienced enhancements in clinical measures; Cohort 1 patients sustained benefits as far out as two years; Cohort 2 patients showed greater symptom relief and improved cardiac function at earlier timepoint; Improvements in multiple clinical parameters of disease including echocardiographic measures of hypertrophy; Three patients had improvements in exercise capacity by at least one measure; Cardiac troponin improved or remained stable in five of six patients; NT-pro BNP improved in three patients; All six evaluable patients achieved reductions in left ventricular mass index (LVMI); Five of six demonstrated reductions in one or more measures of wall thickness Read More | Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Read More | |
TN-201 Fast TrackOrphanRare Pediatric | MYBPC3-associated hypertrophic cardiomyopathy (HCM) | Phase 1b/2 | 2026-06-03 | All evaluable patients experienced enhancements in clinical measures; Cohort 1 patients sustained benefits as far out as two years; Cohort 2 patients showed greater symptom relief and improved cardiac function at earlier timepoint; Improvements in multiple clinical parameters of disease including echocardiographic measures of hypertrophy; Three patients had improvements in exercise capacity by at least one measure; Cardiac troponin improved or remained stable in five of six patients; NT-pro BNP improved in three patients; All six evaluable patients achieved reductions in left ventricular mass index (LVMI); Five of six demonstrated reductions in one or more measures of wall thickness Read More | Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TNYA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TNYA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TNYATenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. Hyllengren, who has over two decades of experience in biotechnology finance, will oversee financial strategy and corporate development. His appointment comes as Tenaya prepares for pivotal clinical trials and aims to advance its genetic medicines for heart disease. Additionally, Hiro Higa will retire but remain as a consultant during the transition.
Read more →TNYATenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics reported interim data from its MyPEAK-1 Phase 1b/2 trial of TN-201, showing significant improvements in patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM). All evaluable patients experienced enhancements in clinical measures, with notable durability in responses. The higher dose cohort exhibited greater symptom relief sooner. TN-201 has been granted PRIME designation by the EMA.
Read more →TNYATenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Tenaya Therapeutics will announce new interim data from its MyPEAK-1 Phase 1b/2 trial of TN-201, a gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM), on June 3, 2026. The company aims to address the underlying genetic causes of HCM, a severe condition affecting many patients. The webcast will provide insights into the trial's findings.
Read more →TNYA▲ +8.8%on this newsshared move
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Tenaya Therapeutics will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Faraz Ali is scheduled to deliver a presentation on June 4 at 3:10 p.m. ET. The event will highlight Tenaya's commitment to developing therapies for heart disease, including their clinical-stage candidates.
Read more →TNYA▼ -8.3%on this news
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Tenaya Therapeutics reported positive interim data from its RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for PKP2-associated ARVC. All patients showed significant reductions in premature ventricular contractions, with a mean decrease of 64%. The therapy was well tolerated, and biopsies indicated effective transduction in heart muscle cells. The European Medicines Agency granted PRIME designation to TN-401, highlighting its potential to address unmet medical needs.
Read more →TNYA▲ +7.4%on this news· ran to +27% by day 1
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics reported its first quarter 2026 financial results, highlighting upcoming clinical milestones for its gene therapies TN-201 and TN-401. The company also presented new preclinical data for TN-301, a small molecule candidate for various cardiac conditions. Additionally, a collaboration with Alnylam aims to identify genetic targets for cardiovascular diseases.
Read more →TNYATenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Tenaya Therapeutics announced that new clinical data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy will be presented at the ASGCT Annual Meeting 2026. The therapy targets adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The presentation will include safety and efficacy data from two dose cohorts, showcasing the potential of TN-401 in treating this condition.
Read more →TNYATenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readout
Tenaya Therapeutics has announced its fourth quarter and full year 2025 financial results, highlighting promising advancements in its gene therapy programs, TN-201 for hypertrophic cardiomyopathy and TN-401 for arrhythmogenic right ventricular cardiomyopathy. The company reported successful safety and efficacy results from recent clinical trials, along with plans for additional updates and regulatory alignment in 2026. Additionally, Tenaya entered a research collaboration with Alnylam Pharmaceuticals, aiming to explore new genetic targets for cardiovascular disease treatments. The company's financial stability is strengthened by a recent funding round, enabling sustained development efforts going into 2027.
Read more →TNYA▲ +7.8%on this newsshared move
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya Therapeutics presented promising preclinical data for TN-301, a selective HDAC6 inhibitor, at the MDA 2026 conference. The data showed TN-301's potential to improve muscle function and address cardiomyopathy in Duchenne muscular dystrophy (DMD). The drug outperformed the approved agent givinostat in animal models, leading Tenaya to plan for Phase 2 clinical development.
Read more →TNYA▲ +40.9%on this news· ran to +54% by day 3shared move
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Tenaya Therapeutics has announced a research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapies. Tenaya will receive up to $10 million upfront, along with potential milestone payments totaling $1.13 billion. This partnership aims to leverage both companies' strengths to develop transformative treatments for heart disease.
Read more →TNYATenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Tenaya Therapeutics will participate in the Leerink Partners Global Healthcare Conference from March 9-11, 2026, in Miami, Florida. CEO Faraz Ali is scheduled for a fireside chat on March 9 at 1:00 pm ET. The event will be accessible via live webcast, with an archived replay available for 30 days post-conference.
Read more →TNYATenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Tenaya Therapeutics has outlined its strategic priorities for 2026, focusing on advancing its gene therapy programs TN-201 and TN-401. The company aims to build on positive interim results from 2025, with key data readouts expected in the first half of 2026. Additionally, Tenaya raised $60 million to support its operations through mid-2027.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics has announced the pricing of its public offering, aiming to raise $60 million through the sale of 50 million units. Each unit consists of a share of common stock and a warrant for additional shares. The proceeds will support the development of clinical candidates TN-201 and TN-401, with the offering expected to close on December 15, 2025.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3shared move
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics announced its intention to conduct a public offering of units consisting of common stock and warrants. The offering is subject to market conditions and may include pre-funded units. Leerink Partners and Piper Sandler are acting as joint bookrunning managers. The company focuses on developing therapies for heart disease, with several clinical-stage candidates in its pipeline.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3shared move
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
Tenaya Therapeutics reported positive interim data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC. The therapy demonstrated a good safety profile and increased PKP2 protein levels in patients. Notably, reductions in arrhythmia burden were observed in patients with over six months of follow-up. A conference call is scheduled to discuss these results further.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3shared move
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
Tenaya Therapeutics announced the lifting of the FDA clinical hold on its MyPEAK-1 Phase 1b/2a trial for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. The company has addressed all FDA concerns and is amending the study protocol to enhance patient monitoring. TN-201 has been well tolerated, and the trial is set to resume dosing soon.
Read more →TNYA▲ +11.7%on this news
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics reported its third quarter 2025 financial results, highlighting advancements in its gene therapy programs, TN-201 and TN-401. Both therapies received positive recommendations from Data Safety Monitoring Boards, indicating confidence in their safety profiles. The company plans to present new data from the MyPEAK-1 trial and discuss interim results from the RIDGE-1 trial in upcoming webcasts.
Read more →TNYA▲ +11.7%on this newsshared move
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics presented interim data from its MyPEAK-1 Phase 1b/2a trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy. The therapy demonstrated a favorable safety profile and significant improvements in hypertrophy measures. However, the FDA has placed the trial on clinical hold, necessitating further follow-up to confirm these findings.
Read more →TNYATenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
Tenaya Therapeutics announced that new clinical data for TN-201 gene therapy will be presented at the AHA 2025 Scientific Sessions. The presentations will cover interim safety and efficacy results from the MyPEAK-1 Phase 1b/2a trial for MYBPC3-associated hypertrophic cardiomyopathy, as well as results from a preclinical study on ischemic heart failure. A conference call is scheduled for November 10, 2025, to discuss these findings.
Read more →TNYATenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Tenaya Therapeutics will participate in the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. CEO Faraz Ali will engage in a fireside chat, and the company will host virtual one-on-one meetings the following day. The event highlights Tenaya's commitment to developing therapies for heart disease.
Read more →TNYATenaya Therapeutics to Participate in Upcoming October Investor Conferences
Tenaya Therapeutics announced its participation in several investor conferences in October. CEO Faraz Ali will discuss emerging trends in cell and gene therapy at the Cell & Gene Meeting on the Mesa and present at the Chardan Annual Genetic Medicines Conference. The company aims to address heart disease through innovative gene therapies.
Read more →TNYA▲ +6.8%on this news· ran to +18% by day 3
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics has granted stock options for 202,000 shares to two new non-executive employees as part of their employment agreement. The options have an exercise price of $1.20 per share, aligning with the company's stock price on September 15, 2025. This grant is part of the NASDAQ Listing Rule 5635(c)(4) and aims to incentivize new hires.
Read more →TNYA▲ +9.3%on this news· ran to +30% by day 3
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Tenaya Therapeutics will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. CEO Faraz Ali is scheduled for a fireside chat, which will be available via live webcast and archived for 30 days. The company focuses on developing therapies for heart disease, including gene therapies for specific conditions.
Read more →TNYATenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Tenaya Therapeutics presented interim data from its MyClimb study at the ESC 2025, focusing on pediatric patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM). The study, the largest of its kind, revealed that 93% of participants had the nonobstructive form of HCM, which lacks approved therapies. Key findings suggest that genotypic status is a significant risk predictor, emphasizing the need for disease-modifying treatments and genetic counseling.
Read more →TNYATenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics, a clinical-stage biotechnology company, will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. CEO Faraz Ali will lead a fireside chat, which will be available via live webcast and archived on the company's website. Tenaya is dedicated to developing therapies for heart disease, with a pipeline that includes gene therapies and small molecule inhibitors.
Read more →TNYATenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Enrollment Complete in Cohorts 1 and 2 of MyPEAK TM -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Sa
Tenaya Therapeutics announced its Q2 2025 financial results and provided updates on its gene therapy clinical trials. Enrollment for both cohorts of the MyPEAK-1 Phase 1b/2 trial of TN-201 for MYBPC3-associated HCM has been completed, with positive safety evaluations allowing for expansion. Similarly, the RIDGE-1 Phase 1b trial for TN-401 began dosing patients following favorable recommendations. Financially, the company reported a net loss of $23.3 million, although it retains a sufficient cash runway into mid-2026 for ongoing R&D activities.
Read more →TNYATenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Tenaya Therapeutics announced that its gene therapies, TN-201 and TN-401, received positive safety evaluations from independent Data Safety and Monitoring Boards (DSMBs), allowing the company to proceed with clinical trials as planned. The MyPEAK-1 Phase 1b/2 trial for TN-201 has completed enrollment in its dose cohorts, with preliminary results suggesting favorable outcomes in heart failure symptoms. The RIDGE-1 Phase 1b trial for TN-401 has also dosed its first patient in a higher cohort, with plans for further patient enrollment and data updates expected in the fourth quarter of 2025.
Read more →TNYATenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Tenaya Therapeutics is set to present five abstracts at the ASGCT 2025 Annual Meeting, showcasing advancements in capsid engineering, prime editing techniques, and improvements in AAV gene therapy manufacturing. Research highlights include a prototype aimed at treating dilated cardiomyopathy and a novel method to enhance manufacturing yields. The developments promise to contribute significantly to the treatment landscape of heart diseases.
Read more →TNYATenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Interim Data from Low Dose Cohort in MyPEAK TM -1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and
Tenaya Therapeutics, based in South San Francisco, reported its first-quarter financial results for 2025, highlighting encouraging interim data from the MyPEAK-1 clinical trial of gene therapy TN-201. These findings included improvements in patient classifications and significant DNA transduction and RNA expression. Additionally, the company's cash runway has been extended to support operations into the latter half of 2026. However, this financial outlook comes alongside a net loss of $26.9 million and company restructuring plans that entail workforce reductions.
Read more →TNYATenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
Tenaya Therapeutics announced interim data from the RIDGE study, the largest natural history study of PKP2-associated ARVC, at the Heart Rhythm Society meeting. The study reveals that current treatments inadequately manage arrhythmias and disease progression, with a majority of patients showing severe heart structural changes. However, promisingly, many participants are eligible for the investigational TN-401 gene therapy, aimed at addressing the root causes of this condition. The findings underscore the urgent need for effective therapies in this patient population.
Read more →TNYA▼ -11.3%on this news
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Tenaya Therapeutics presented promising interim data from their MyPEAK-1 Phase 1b/2 clinical trial of TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the American College of Cardiology Annual Meeting. Initial results indicate that TN-201 is well-tolerated and shows encouraging efficacy, as evidenced by improvements in cardiac function and RNA expression. All patients have achieved significant clinical improvement, reaching NYHA Class I by the end of the trial period. Further data is anticipated later in the year as the study continues to enroll additional cohorts.
Read more →TNYA▲ +10%on this news
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Tenaya Therapeutics has published promising preclinical data for its gene therapy candidate TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM). The study found that TN-201 significantly increased MyBP-C protein levels, improving various cardiac function parameters and even reversing left ventricular hypertrophy in models of the disease. TN-201 is currently undergoing clinical evaluation in the MyPEAK-1 Phase 1b/2 clinical trial. The findings provide strong support for the clinical development of this novel therapy.
Read more →TNYATenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
Tenaya Therapeutics announced that it will present new clinical and disease burden data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific Session from March 29-31, 2025. The company will share data from the MyPEAK-1 Phase 1b/2 clinical trial of its AAV9-based gene therapy, TN-201. The late-breaking sessions will feature results from initial patient assessments and a poster presentation detailing disease burden differences among HCM patients. The sessions will highlight the company's commitment to developing curative therapies for heart disease.
Read more →TNYA▲ +11.1%on this news· ran to +47% by day 3
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK -1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Assoc
Tenaya Therapeutics announced its financial results for Q4 and the full year 2024, revealing a net loss of $23.8 million in the last quarter and $111.1 million over the year. The company has initiated dosing in Cohort 2 of the MyPEAK-1 clinical trial for its TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and early data from Cohort 1 has been accepted for presentation at the American College of Cardiology meeting. Furthermore, successful financing efforts have extended the company's cash runway into mid-2026, allowing continued focus on gene therapy developments.
Read more →TNYA▼ -6.2%on this news· ran to -56% by day 1
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
Tenaya Therapeutics, a clinical-stage biotechnology company, is set to participate in two significant investor conferences: TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. CEO Faraz Ali will represent the company in these events, sharing insights into Tenaya's mission to develop therapies addressing heart disease. The presentations are expected to enhance visibility and interest in Tenaya's portfolio, which includes various gene therapies and small molecules targeting heart conditions.
Read more →TNYA▼ -6.2%on this news· ran to -56% by day 1
Tenaya Therapeutics Announces Pricing of Public Offering South San Francisco, Calif.
Tenaya Therapeutics has announced the pricing of a public offering consisting of 75,000,000 units priced at $0.70 each, aiming to raise about $52.5 million. The company plans to use the proceeds to further develop its clinical candidates, particularly TN-201 and TN-401. The offering will close around March 5, 2025, subject to customary conditions. Leerink Partners and Piper Sandler are managing the offering. Tenaya specializes in developing therapies for heart disease and has a diversified pipeline of treatments.
Read more →TNYATenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
Tenaya Therapeutics has been awarded an $8 million grant from the California Institute for Regenerative Medicine to fund their ongoing RIDGE-1 clinical trial of TN-401. This gene therapy targets arrhythmogenic right ventricular cardiomyopathy caused by mutations in the PKP2 gene. The funding aims to address high clinical trial costs, reflecting confidence in the potential of TN-401 as a treatment for this severe condition. Initial data from the trial is anticipated in the second half of 2025.
Read more →TNYATenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
Tenaya Therapeutics has unveiled its strategic priorities for 2025, focusing on advancing its gene therapies TN-201 and TN-401 aimed at treating cardiomyopathies. The company has initiated dosing in cohort 2 of the MyPEAK-1 trial for TN-201 and expects to report additional data from cohort 1 in the first half of 2025. Initial clinical data from TN-401 is expected to emerge in the second half of 2025, highlighting their continued commitment to addressing the underlying causes of heart disease. Tenaya aims to continue momentum in clinical trial enrollment and patient outcome reporting throughout the year.
Read more →TNYA▼ -51%on this news
Tenaya Therapeutics Reports Promising Early Data from MyPEAK -1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3 -Associated Hypertrophic Cardiomyopathy TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Dem
Tenaya Therapeutics announced positive early results from its MyPEAK-1 clinical trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy. Preliminary data from three patients indicated TN-201 was well tolerated and showed an increase in RNA and protein expression over time. Moreover, clinical measures of cardiac function remained stable or showed improvement in some patients. The company plans to continue monitoring these patients and intends to present further results from higher dosage cohorts in the future.
Read more →TNYATenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Tenaya Therapeutics will announce initial data from the MyPEAK-1 Phase 1b/2 clinical trial of their TN-201 gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM) on December 17, 2024. The company positions itself as a leader in developing innovative therapies for heart diseases. A live conference call and webcast will be held to discuss the results, with a replay available afterward. This announcement represents a significant step in the clinical development of gene therapies for heart conditions.
Read more →TNYA▲ +24.4%on this news· ran to +50% by day 3
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics announced the dosing of the first patient in their RIDGE-1 Phase 1b clinical trial of TN-401, a gene therapy aimed at treating arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. The trial, which is currently enrolling participants at six clinical sites, will assess the safety and preliminary efficacy of TN-401, with initial data expected in 2025. TN-401 is designed to deliver a functional PKP2 gene to address the underlying cause of the disease, potentially improving patients' quality of life by addressing severe arrhythmias and reducing the need for chronic medications. The trial represents a significant milestone for Tenaya in their mission to develop curative therapies for heart disease.
Read more →TNYATenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2
Tenaya Therapeutics announced its financial results for Q3 2024 and provided updates on its MyPEAK-1 clinical trial for TN-201 gene therapy, which received a favorable safety evaluation and approval for dose escalation. The company has adjusted the eligibility criteria for the trial to potentially enhance patient enrollment. Tenaya plans to present early clinical data from the first cohort of patients in December 2024. Despite a net loss reported during the quarter, the company is well-capitalized to support operations until mid-2025.
Read more →TNYA▲ +22.9%on this news
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Tenaya Therapeutics has announced updates regarding its Phase 1b/2 MyPEAK-1 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy. The trial's independent Data Safety and Monitoring Board has endorsed dose escalation and broader eligibility criteria. Initial results from Cohort 1 are anticipated in December 2024, focusing on safety, tolerability, and biomarker analysis. Tenaya also highlights the significant medical burden of MYBPC3-associated HCM in children and adolescents.
Read more →TNYA▼ -5.6%on this news
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
Tenaya Therapeutics, a biotechnology company focused on curing heart disease, announced that its CEO, Faraz Ali, will participate in several investment conferences. These include the Morgan Stanley Global Healthcare Conference, the World Medical Innovation Forum, and Chardan’s Genetic Medicines Conference, taking place in September and October 2024. The company aims to present its advancements in gene therapy and cardiovascular research, emphasizing its commitment to developing curative treatments. Access to the webcasts from these events will also be available on Tenaya's website.
Read more →TNYA▲ +5.1%on this news· ran to +20% by day 3
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrop
Tenaya Therapeutics reported its financial results for the second quarter of 2024, highlighting its commitment to advancing gene therapies for heart conditions. The company received Rare Pediatric Disease Designation from the FDA for TN-201, and established a $45 million credit facility to support clinical developments. Anticipated milestones include initial data from TN-201's trial in late 2024 and patient enrollment for TN-401's trial. However, there was an increase in net loss compared to the previous year, alongside notable executive departures.
Read more →TNYA▲ +8.1%on this news
Tenaya Therapeutics Announces Research Leadership Updates
Tenaya Therapeutics has announced leadership changes in its research team, promoting Kathy Ivey, Ph.D. to Senior Vice President of Research, while Timothy Hoey, Ph.D. transitions to an advisory role. In addition, Barry J. Byrne, M.D., Ph.D. has joined the Scientific Advisory Board, bringing significant expertise in pediatric cardiology and genetic therapies. The company also acknowledged the service of Jin-Long Chen, Ph.D. who is stepping down from the Board of Directors. These changes reflect Tenaya's ongoing commitment to advancing its mission in developing innovative therapies for heart disease.
Read more →TNYATenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
Tenaya Therapeutics will be represented by CEO Faraz Ali at the TD Cowen Genetic Medicines & RNA Summit on June 21, 2024. The conference will be webcast for public accessibility, emphasizing the firm's commitment to transparency. Tenaya specializes in developing gene therapies for heart disease, including advanced candidates aimed at specific genetic cardiovascular disorders. Their participation in this summit underscores their ongoing efforts to enhance visibility and attract investment in their innovative therapies.
Read more →TNYATenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Initial Data from Ongoing MyPEAK TM -1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE T
Tenaya Therapeutics reported its financial results for Q1 2024, highlighting a $47 million funding gain and advancements in its clinical trials. The company is focusing on the MyPEAK-1 Phase 1b trial for its gene therapy TN-201, with initial data anticipated by late 2024, and has activated sites for the TN-401 RIDGE-1 trial. Despite these advancements, Tenaya faces challenges with a net loss of $32.2 million and is implementing significant cost-cutting measures, including workforce reductions. The firm has a promising cash runway into the second half of 2025 to support ongoing projects.
Read more →TNYATenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics is set to present seven abstracts at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, focusing on its advancements in capsid engineering, gene editing, and manufacturing of AAV-based genetic medicines for heart disease. The presentations will highlight new insights and data from research efforts. Notably, Tenaya's gene editing therapy has shown promise in preclinical models for treating specific types of cardiomyopathies. The company's integrated capabilities underscore its commitment to developing potentially curative therapies for heart disease.
Read more →TNYATenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
Tenaya Therapeutics announced the publication of preclinical data for its TN-401 gene therapy in Nature Communications Medicine. This therapy targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) and has demonstrated efficacy in a severe mouse model, including normalization of heart rhythms and disease reversal. The company plans to initiate a Phase 1b clinical trial, RIDGE-1, in the second half of 2024, aiming to evaluate safety and efficacy in patients. The findings highlight the potential of TN-401 to address the underlying causes of ARVC, which affects patient quality of life.
Read more →TNYATenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Initial Data from Ongoing MyPeak -1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 202
Tenaya Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting advancements in its genetic therapies for heart disease. The company is on track to share initial data from its ongoing MyPeak-1 Phase 1b trial for TN-201 in 2024 and plans to dose the first patient in the RIDGE-1 trial for TN-401 within the same timeframe. A recent financing round netted $47 million, extending Tenaya's cash runway into the second half of 2025. Despite these advancements, the company reported a significant net loss for the year, raising concerns about its financial sustainability.
Read more →TNYA▲ +9%on this newsshared move
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
Tenaya Therapeutics has published promising preclinical research on its HDAC6 inhibitor, TN-301, in Nature Communications. The study showcases the inhibitor's ability to reverse symptoms of heart failure with preserved ejection fraction (HFpEF) and highlights its efficacy both as a standalone treatment and in combination with empagliflozin. This research underscores the potential of TN-301 to address significant unmet needs in heart disease treatment. Additionally, positive results from prior clinical trials suggest a strong foundation for further development in HFpEF therapies.
Read more →TNYA▲ +16.1%on this news· ran to +29% by day 1
Tenaya Therapeutics Announces Pricing of Underwritten Offering South San Francisco, Calif.
Tenaya Therapeutics announced the pricing of an underwritten offering of 8,888,890 shares of its common stock at $4.50 per share. The company expects to raise approximately $50 million from this offering, which is set to close on or about February 12, 2024. The offering sees participation from a range of investors including major firms such as BlackRock and RA Capital Management. This funding will support Tenaya's mission to develop therapies targeting heart disease.
Read more →TNYA▼ -5.3%on this news
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Tenaya Therapeutics, a biotechnology company specializing in heart disease therapies, announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Faraz Ali will present on January 11, 2024, at 9:45 am PT. The event will be webcast live and available for replay on the company website for approximately 30 days. Tenaya is advancing innovative therapies, including gene therapies for specific cardiovascular conditions.
Read more →TNYATenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
Tenaya Therapeutics, a clinical-stage biotechnology company, has announced that CEO Faraz Ali will participate in the 35th Annual Piper Sandler Healthcare Conference in New York on November 28, 2023. The event will focus on Tenaya's mission to develop therapies that address heart disease. A webcast of the conference will be available, allowing stakeholders to access the company's insights. This participation highlights Tenaya's commitment to advancing its innovative therapies in the biotechnology sector.
Read more →TNYATenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Commenced Patient Dosing in MyPeak-1 TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Po
Tenaya Therapeutics has reported its financial results for Q3 2023 and announced significant progress in its clinical trials. The company commenced patient dosing for TN-201 in the MyPeak-1 Phase 1b trial aimed at treating MYBPC3-associated hypertrophic cardiomyopathy. Additionally, TN-401 received FDA clearance to begin clinical testing and was granted Fast Track designation. They presented positive Phase 1 results for TN-301 at the HFSA Annual Scientific Meeting and maintain a strong cash position projected to fund operations until mid-2025.
Read more →TNYA▼ -5.7%on this news
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics has received FDA clearance to begin clinical trials for TN-401, a gene therapy targeting PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The therapy aims to restore normal PKP2 protein levels, addressing the genetic cause of this dangerous heart condition. Initial preclinical studies have shown promising results, indicating robust reductions in ventricular arrhythmias and improved survival rates. The company plans to commence the RIDGE-1 Phase 1b trial, focusing on safety and efficacy in a selected group of patients.
Read more →TNYATenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
Tenaya Therapeutics has presented new clinical and preclinical data for its HDAC6 inhibitor, TN-301, at the 2023 HFSA Annual Scientific Meeting. The Phase 1 clinical trial demonstrated safety, tolerability, and robust target engagement in healthy participants, along with a potential for once-daily dosing. Preclinical studies show additive benefits of TN-301 when used with empagliflozin in models of heart failure with preserved ejection fraction (HFpEF), highlighting its differentiated mechanism of action. Tenaya aims to address the limited treatment options available for HFpEF patients with this innovative therapy.
Read more →TNYATenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Tenaya Therapeutics has announced the dosing of the first patient in its MyPeak-1 Phase 1b clinical trial, which assesses the efficacy of TN-201 gene therapy for the treatment of MYBPC3-associated hypertrophic cardiomyopathy. This gene therapy aims to deliver a full-length copy of the MYBPC3 gene to heart muscle cells, potentially improving heart function and patient outcomes. Initial data from the trial is expected to be shared in 2024, contributing to the understanding and treatment of this genetic condition. The company emphasizes its commitment to addressing the genetic causes of heart disease through innovative therapies.
Read more →TNYATenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
Tenaya Therapeutics has published preclinical research in the journal Circulation, highlighting the potential of its cellular reprogramming approach for cardiac regeneration. The study indicates the use of a novel adeno-associated viral vector to reprogram cardiac fibroblasts into cardiomyocytes, potentially improving heart function in models of myocardial infarction. The research demonstrates significant improvements sustained over time, marking a crucial advance in addressing heart disease. The company continues to advance its research efforts aimed at developing innovative therapies for heart conditions.
Read more →TNYA▲ +6.1%on this news
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
Tenaya Therapeutics has announced its intention to present data on its drug candidates TN-301 and TN-201 at two upcoming scientific meetings in Cleveland, Ohio. The TN-301 trial results indicate it was well tolerated, with achieved target engagement, while TN-201 is being designed as a gene therapy for patients with hypertrophic cardiomyopathy. The presentations are scheduled for October 6-9, 2023, highlighting the company's efforts to develop potential therapies addressing heart disease.
Read more →TNYA▼ -5.4%on this news· ran to -17% by day 3
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
Tenaya Therapeutics, a clinical-stage biotechnology company, will participate in the 21st Annual Morgan Stanley Global Healthcare Conference on September 12, 2023. CEO Faraz Ali is set to represent the company during the event in New York City. The conference serves as a platform for Tenaya to share its innovations in developing therapies for heart disease. The company is advancing various gene therapies and other treatment modalities to address cardiovascular disorders.
Read more →TNYATenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 A
Tenaya Therapeutics reported its financial results for the second quarter of 2023, confirming the upcoming dosing of the first patient in its Phase 1b trial for TN-201, expected to occur in Q3 2023. The company has also confirmed that data from its Phase 1 clinical trial of TN-301 is set for presentation at the Heart Failure Society of America's annual meeting. In addition, an Investigational New Drug application for TN-401 is anticipated in the latter half of 2023. Despite a net loss of $33.3 million for the quarter, Tenaya has a solid cash position to support operations until mid-2025.
Read more →TNYATenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference
Tenaya Therapeutics, a clinical-stage biotechnology company focused on heart disease therapies, announced its participation in the 43rd Annual Canaccord Genuity Growth Conference in Boston on August 9, 2023. The event will feature a presentation by senior management, and a webcast will be available for 90 days afterward. Tenaya's pipeline includes gene therapies for various cardiac conditions and a focus on innovative treatment modalities.
Read more →TNYATenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Seco
Tenaya Therapeutics has reported its first quarter 2023 financial results, highlighting recent advancements in its clinical programs. The company received FDA Fast Track designation for its TN-201 gene therapy and completed dosing in its Phase 1 trial for TN-301, with data expected later this year. Furthermore, Tenaya established a Technical Advisory Board to enhance its manufacturing capabilities and welcomed noted researchers to its Scientific Advisory Board.
Read more →TNYA▲ +12.4%on this news
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting
Tenaya Therapeutics announced the acceptance of several abstracts for presentation at the ASGCT 26th Annual Meeting, highlighting its advancements in AAV manufacturing, capsid engineering, and gene editing. The company showcased innovations aimed at enhancing its capabilities for developing gene therapies for heart disease. During the event, Tenaya plans to present data on its novel AAV approaches and a gene editing strategy addressing cardiomyopathy, further underscoring its commitment to tackling cardiovascular conditions.
Read more →TNYA▼ -11.3%on this newsshared move
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
Tenaya Therapeutics has announced that the FDA has granted Fast Track designation for its gene therapy candidate TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM). This designation is intended to expedite the development and review processes for serious medical conditions with unmet needs. The company is preparing for the Phase 1b clinical trial, expected to start dosing patients in the third quarter of 2023, building on positive preclinical study results. TN-201 is designed to address the underlying genetic cause of HCM by delivering a functional MYBPC3 gene to patients.
Read more →TNYA▲ +22.8%on this news
Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Tenaya Therapeutics, a clinical-stage biotechnology company, announced its participation in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place on April 24-25, 2023. CEO Faraz Ali will take part in a panel discussing gene therapy at the event. The company is dedicated to developing potentially curative therapies for heart disease, emphasizing its innovative platforms and pipeline of novel therapies targeting both rare and prevalent cardiovascular conditions.
Read more →TNYA▼ -7%on this news· ran to -21% by day 3
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter
Tenaya Therapeutics reported its financial results for Q4 and full year 2022, highlighting significant developments such as the FDA's clearance of TN-201's IND, which paves the way for clinical trials starting in Q3 2023. The company has commenced dosing for its TN-301 program and expects to provide data later in 2023. Tenaya ended 2022 with a strong cash position of $204 million, adequate to fund operations into early 2025, despite reporting a net loss of $123.7 million for the year.
Read more →TNYATenaya Therapeutics to Participate in Upcoming Investor Conferences
Tenaya Therapeutics, a clinical-stage biotechnology company, announced its participation in the SVB Securities Global Biopharma Conference and Cowen's 43rd Annual Health Care Conference. The company aims to develop therapies for heart disease through gene therapy, cellular regeneration, and precision medicine. These conferences provide a platform for Tenaya to connect with investors and showcase their innovative work in addressing cardiovascular disorders.
Read more →TNYATenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
Tenaya Therapeutics announced the FDA's clearance of its IND application for TN-201, which aims to treat MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company plans to initiate a Phase 1b clinical trial for the gene therapy in symptomatic adults later this year, with initial data expected in 2024. Additionally, the firm revealed it has sufficient clinical trial material to support the Phase 1b study and extended its cash runway into early 2025, allowing for continued development of its gene therapy programs.
Read more →TNYATenaya Therapeutics Appoints Amy Burroughs to Board of Directors SOUTH SAN FRANCISCO, Calif., –
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors SOUTH SAN FRANCISCO, Calif., December 7, 2022 Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that add
Read more →TNYA▲ +7.1%on this news
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVC Expect to submit TN-401 IND application to th
Read more →TNYATenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, toda
Read more →TNYATenaya Therapeutics Announces Closing of Public Offering
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, anno
Read more →TNYA▲ +6.8%on this news· ran to +53% by day 3
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End South San Francisco, Calif. Novembe
Read more →TNYA▼ -17.9%on this news
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today
Read more →TNYATenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, anno
Read more →TNYA▼ -10.4%on this newsshared move
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, ann
Read more →TNYA▼ -10.4%on this newsshared move
Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, ann
Read more →TNYA▼ -7.2%on this news
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced
Read more →TNYA▼ -7.2%on this news
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced clearanc
Read more →TNYATenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second H
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline
Read more →TNYATenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with IND Filing on Track for 2H 2022 SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOB
Read more →TNYA▼ -12%on this news
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart R
Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 South San Francisco, Calif. May 11, 2022 Tenay
Read more →TNYA▼ -5.8%on this news
Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates Strengthened Leadership Team with the Additions of Sunita Sethi as Senior Vice President of Regulatory Affairs
Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates Strengthened Leadership Team with the Additions of Sunita Sethi as Senior Vice President of Regulatory Affairs and Naymisha Patel as Senior Vice President of Quality Sou
Read more →TNYA▲ +9%on this news
Tenaya Therapeutics appoints Karah Parschauer, J.D., to its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
Tenaya Therapeutics appoints Karah Parschauer, J.D., to its Board of Directors and Joanna Auch as Senior Vice President of People and Culture SOUTH SAN FRANCISCO, Calif., December 22, 2021 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to disc
Read more →TNYA▼ -8.3%on this news
Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE)
Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Nov. 22, 2021 Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies tha
Read more →TNYATenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates - Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-20
Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates SOUTH SAN FRANCISCO, Calif. - (BUSINESS WIRE) -November 10, 2021-- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver cur
Read more →TNYATenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates TN-201 MYBPC3 gene therapy product candidate for the leading genetic cause of hypertrophic cardiomyopathy granted Orphan Dru
Tenaya Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) September 8, 2021 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curati
Read more →TNYATenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., August 3, 2021 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission t
Read more →Competitive Position
How TNYA ranks across every disease it competes inCompetitive Position is a premium feature
See how TNYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial